This open label extension study is designed to provide continued access to ANAVEX 2-73 for eligible subjects with mild to moderate Alzheimer's Disease who have previously participated in the Anavex sponsored study ANAVEX2-73-002.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
21
Melbourne Health - The Royal Melbourne Hospital
Melbourne, Victoria, Australia
Austin Health - Heidelberg Repatriation Hospital
Melbourne, Victoria, Australia
Caulfield Hospital
Melbourne, Victoria, Australia
Nucleus Network- Centre for Clinical Studies
Melbourne, Victoria, Australia
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Safety
Time frame: Up to 208 weeks
Score from MMSE (Mini-mental state examination score)
Exploratory Efficacy
Time frame: Baseline; Weeks: 13, 26, 39, 52, 65, 78, 91, 104, 117, 130, 143, 156, 169, 182, 195, 208
Score from ADCS-ADL (Alzheimer's Disease Co-operative Study - Activities of Daily Living Inventory)
Exploratory Efficacy
Time frame: Baseline; Weeks: 13, 26, 39, 52, 65, 78, 91, 104, 117, 130, 143, 156, 169, 182, 195, 208
HAM-D Score (Hamilton Psychiatric Rating Scale for Depression)
Exploratory Efficacy
Time frame: Baseline; Weeks: 13, 26, 39, 52, 65, 78, 91, 104, 117, 130, 143, 156, 169, 182, 195, 208
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
St. Vincent's Hospital
Melbourne, Victoria, Australia